IBD5 polymorphisms in inflammatory bowel disease: Association with response to infliximab

doi:10.3748/wjg.v11.i8.1187

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 8

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3001)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-3) series.

Item

Count

PDF

338

HTML

2435

Tables (1-3)

228

Sum=3001

Feb 28, 2005 (publication date) through Nov 5, 2024

Times Cited of This Article

Times Cited (59)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Reports

World J Gastroenterol. Feb 28, 2005; 11(8): 1187-1192
Published online Feb 28, 2005. doi: 10.3748/wjg.v11.i8.1187

Table 1 Genotype frequencies of the IBD5 SNPs in Crohn’s disease patients and controls.

	TT (%)	GT (%)	GG (%)
Controls (n = 511)	170 (33.3)	236 (46.2)	105 (20.5)
CD patients (n = 274)	74 (27)	136 (49.6)	64 (23.4)
CD-L₁ (n = 133) terminal ileum + UG	41 (30.8)	66 (49.6)	26 (19.6)
CD-L₂ (n = 46) colon	12 (26.1)	23 (50)	11 (23.9)
CD-L₃ (n = 95) ileocolon	21 (22.1)	47 (49.5)	27 (28.4)^a
CD-B₁ (n = 119) inflammatory	36 (30.2)	60 (50.4)	23 (19.3)
CD-B₂ (n = 44) stricturing	14 (31.8)	22 (50)	8 (18.2)
CD-B₃ (n = 110) fistulizing	24 (21.3)	53 (48.9)	33 (30)^c
CD-perianal (n = 47)	10 (21.3)	23 (48.9)	14 (29.8)
CD-non perianal (n = 227)	64 (28.2)	113 (49.8)	50 (22)

(GG+ GT) vs TT:

^aP<0.05; OR (CI) = 1.76 (1.02-3.05) compared to controls. (GG+ GT) vs TT:

^cP<0.05; OR (CI) = 1.79 (1.07-3.00) compared to controls.

Table 2 Genotype frequencies of the IBD5 SNPs in NOD2/CARD15-negative Crohn’s disease patients and ethnically-matched controls.

	TT (%)	GT (%)	GG (%)
Controls (n = 511)	170 (33.3)	236 (46.2)	105 (20.5)
CD patients (n = 140)	32 (22.9)	69 (49.3)	39 (27.9)^a
CD-L₁ (n = 55) terminal ileum + UG	16 (29.1)	25 (45.5)	14 (25.5)
CD-L₂ (n = 31) colon	8 (25.8)	15 (48.4)	8 (25.8)
CD-L₃ (n = 54) ileocolon	8 (14.8)	29 (53.7)	17 (31.5)^b
CD-B₁ (n = 65) inflammatory	17 (26.1)	33 (50.8)	15 (23.1)
CD-B₂ (n = 15) stricturing	6 (40)	7 (46.7)	2 (13. 3 )
CD-B₃ (n = 59) fistulizing	9 (15.25)	28 (47.5)	22 (37.3)^d
CD-perianal (n = 34)	6 (17.7)	19 (55.9)	9 (26.5)
CD-non perianal (n = 106)	26 (24.5)	50 (47.2)	30 (28.3)

(GG+GT) vs TT:

^aP<0.05; OR (CI) = 1.68 (1.07-2.66) compared to controls. (GG+GT) vs TT:

^bP<0.01; OR (CI) = 2.87 (1.27-6.73) compared to controls. (GG+GT) vs TT:

^dP<0.01; OR (CI) = 2.77 (1.28-6.2) compared to controls.

Table 3 Patients’ characteristics at the time of infliximab treatment: the differential response to infliximab therapy in CD patients depends on their 5q31 genotype.

	Responder (n = 25)	Non-responder (n = 15)	P
Demographics
Mean age, yr (range)	35 (21-66)	40 (17-68)	0.21
Mean duration of disease, yr (range)	10 (1-27)	12 (1-31)	0.37
Male:Female	13:12	6:09	0.46
Smoker, n (%)	13 (52)	8 (53.3)	0.93
Extraintestinal	13 (52)	7 (46)	0.92
manifestations, n (%)
Previous surgery, n (%)	14 (56)	9 (60)	0.8
Disease distribution
Small bowel only, n (%)	9 (36)	4 (26.7)	0.54
Colon only, n (%)	3 (12)	2 (13.3)	1
Colon and small bowel, n (%)	13 (52)	9 (66)	0.62
Indication for infliximab
Inflammatory disease only, n (%)	7 (28)	6 (40)	0.62
Fistulizing disease only, n (%)	10 (40)	7 (46.7)	1
Inflammatory and	8 (32)	2 (13.3)	0.27
fistulizing disease, n (%)
Concomitant medication
6-mercaptopurine, azathioprine,	17 (68)	13 (86.7)	0.27
methotrexate, n (%)
Mesalamine, n (%)	7 (28)	4 (26.7)	0.52
Corticosteroid, n (%)	6 (24)	5 (33.3)	1
5q31 genotype
Homozygous wild type, n (%)	6 (24)	3 (20)	1
Heterozygous, n (%)	16 (64)	5 (33.3)	0.1
Homozygous mutant, n (%)	3 (12)	7 (46.7)	0.024^a

^aP<0.05, RR (CI) = 3.88 (1.18-12.8).

Citation: Urcelay E, Mendoza JL, Martínez A, Fernández L, Taxonera C, Díaz-Rubio M, de la Concha EG. IBD5 polymorphisms in inflammatory bowel disease: Association with response to infliximab. World J Gastroenterol 2005; 11(8): 1187-1192
URL: https://www.wjgnet.com/1007-9327/full/v11/i8/1187.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i8.1187